214 related articles for article (PubMed ID: 22050023)
1. Role of tyrosine kinase inhibitors in the management of high-grade gliomas.
Ahluwalia MS; Patel M; Peereboom DM
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1739-48. PubMed ID: 22050023
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors in children with malignant gliomas.
Herrington B; Kieran MW
Pediatr Blood Cancer; 2009 Sep; 53(3):312-7. PubMed ID: 19434732
[TBL] [Abstract][Full Text] [Related]
3. New treatment strategies for malignant gliomas.
Sathornsumetee S; Rich JN
Expert Rev Anticancer Ther; 2006 Jul; 6(7):1087-104. PubMed ID: 16831080
[TBL] [Abstract][Full Text] [Related]
4. Emerging targeted treatments for malignant glioma.
Mulholland PJ; Thirlwell C; Brock CS; Newlands ES
Expert Opin Emerg Drugs; 2005 Nov; 10(4):845-54. PubMed ID: 16262566
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
Newton HB
Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy for high-grade gliomas.
Galanis E; Buckner J
Br J Cancer; 2000 Apr; 82(8):1371-80. PubMed ID: 10780513
[No Abstract] [Full Text] [Related]
7. Role of tyrosine kinase inhibitors in cancer therapy.
Arora A; Scholar EM
J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
[TBL] [Abstract][Full Text] [Related]
8. Recurrent high-grade glioma: a diagnostic and therapeutic challenge.
Walbert T; Mikkelsen T
Expert Rev Neurother; 2011 Apr; 11(4):509-18. PubMed ID: 21469924
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?
Karpel-Massler G; Schmidt U; Unterberg A; Halatsch ME
Mol Cancer Res; 2009 Jul; 7(7):1000-12. PubMed ID: 19584260
[TBL] [Abstract][Full Text] [Related]
10. Cell surface receptors in malignant glioma.
Li YM; Hall WA
Neurosurgery; 2011 Oct; 69(4):980-94; discussion 994. PubMed ID: 21522029
[TBL] [Abstract][Full Text] [Related]
11. Evolving strategies: future treatment of glioblastoma.
Chamberlain M
Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.
Nelson MH; Dolder CR
Ann Pharmacother; 2006 Feb; 40(2):261-9. PubMed ID: 16418322
[TBL] [Abstract][Full Text] [Related]
13. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
Engelman JA; Settleman J
Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754
[TBL] [Abstract][Full Text] [Related]
14. Promising new therapies for malignant gliomas.
Fine HA
Cancer J; 2007; 13(6):349-54. PubMed ID: 18032970
[TBL] [Abstract][Full Text] [Related]
15. New therapeutic agents in the treatment of recurrent high-grade gliomas.
Brandes AA; Pasetto LM
Forum (Genova); 2000; 10(2):121-31. PubMed ID: 10875974
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy of gliomas.
Kaye AH; Laidlaw JD
Curr Opin Neurol Neurosurg; 1992 Aug; 5(4):526-33. PubMed ID: 1515691
[TBL] [Abstract][Full Text] [Related]
17. Current and future directions for Phase II trials in high-grade glioma.
Alexander BM; Lee EQ; Reardon DA; Wen PY
Expert Rev Neurother; 2013 Apr; 13(4):369-87. PubMed ID: 23545053
[TBL] [Abstract][Full Text] [Related]
18. Recent development in chemotherapy of paediatric brain tumours.
Grill J; Bhangoo R
Curr Opin Oncol; 2007 Nov; 19(6):612-5. PubMed ID: 17906461
[TBL] [Abstract][Full Text] [Related]
19. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
20. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.
Steeghs N; Nortier JW; Gelderblom H
Ann Surg Oncol; 2007 Feb; 14(2):942-53. PubMed ID: 17103252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
